NCT07938619
Tafasitamab, Lenalidomide, Rituximab, and Orelabrutinib for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Complete response rate (CRR)
Timeframe: Up to 12 cycles ( each cycle is 28 days)
Secondary (9)
Objective response rate (ORR)
Disease control rate (DCR)
Duration of Response (DoR)
Duration of Complete Response (DoCR)
Progression-free survival (PFS)
Show 4 moreShow less
Overall survival (OS)
Time to Response (TTR)
Adverse events
Change in Quality of Life
Arms and interventions
Tafasitamab in combination with Lenalidomide, Rituximab and OrelabrutinibExperimental
Participants will receive tafasitamab in combination with lenalidomide, rituximab and orelabrutinib for 4 cycles, and then receive tafasitamab and lenalidomide for additional 8 cycles. Each treatment cycle is 28 days.
Drugs: Tafasitamab, Lenalidomide, Rituximab, Orelabrutinib
Sites
3 sites in 1 country